C-Myc Expression in Oral Squamous Cell Carcinoma: Molecular Mechanisms in Cell Survival and Cancer Progression.

Cal-27 c-Myc doxorubicin squamous cell carcinoma tumor microenvironment

Journal

Pharmaceuticals (Basel, Switzerland)
ISSN: 1424-8247
Titre abrégé: Pharmaceuticals (Basel)
Pays: Switzerland
ID NLM: 101238453

Informations de publication

Date de publication:
19 Jul 2022
Historique:
received: 19 05 2022
revised: 15 07 2022
accepted: 16 07 2022
entrez: 27 7 2022
pubmed: 28 7 2022
medline: 28 7 2022
Statut: epublish

Résumé

Oral squamous cell carcinoma (OSCC) represents 90% of malignant epithelial cancer that occurs in the oral cavity. The c-Myc factor is expressed in multiple types of cancer, comprising head and neck squamous cell carcinoma (HNSCC), where it plays a fundamental role in tumor prognosis and in the self-renewal of tumor stem cells. However, the role of c-Myc in controlling OSCC cells is not well-known. The aim of the present study is the evaluation of the biological roles and regulatory mechanism of c-Myc in the pathogenesis of OSCC. Results indicated that c-Myc, c-Jun, Bcl-2, hypoxia inducible factor-1α (HIF-1α), vascular endothelial growth factor (VEGF), matrix metalloproteinase-9 (MMP-9), ERK 1/2 and pERK1/2 were overexpressed in a cellular model of squamous cell carcinoma, Cal-27. Doxorubicin (Doxo), a common chemotherapeutic agent, inhibited cell invasion, hypoxia, angiogenesis and inflammation in a cellular model of Cal-27 cells as indicated by downregulation of MMP-9, VEGF, ERK 1/2 and pERK 1/2 as well as promoted apoptosis as evidenced by the downregulation of Bcl-2 protein. This work aimed at underlying the functional relevance of c-Myc in OSCC and the HIF-Myc collaboration by integrating the knowledge on this molecular link in an OSCC tumor microenvironment. The results obtained showed for the first time the vital role of c-Myc in Cal-27 in cell survival/proliferation and tumor growth as well as the negative regulatory effect of Doxo against c-Myc signaling pathway.

Identifiants

pubmed: 35890188
pii: ph15070890
doi: 10.3390/ph15070890
pmc: PMC9316231
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Cell Death Dis. 2022 Apr 12;13(4):338
pubmed: 35414060
Int J Biol Macromol. 2020 May 1;150:1000-1010
pubmed: 31751739
Oxid Med Cell Longev. 2021 Jan 19;2021:6679708
pubmed: 33542783
Annu Rev Genet. 1986;20:361-84
pubmed: 3028245
Front Cell Dev Biol. 2020 Nov 05;8:590576
pubmed: 33251216
Clin Cancer Res. 2017 Jun 15;23(12):3120-3128
pubmed: 27965308
Curr Top Dev Biol. 2006;76:217-57
pubmed: 17118268
J Cell Biochem. 2011 Sep;112(9):2508-17
pubmed: 21557297
Adv Hematol. 2012;2012:524308
pubmed: 21941553
Front Oncol. 2020 Nov 26;10:581208
pubmed: 33324557
Oncogene. 1989 Dec;4(12):1463-8
pubmed: 2687767
Oral Oncol. 2018 May;80:23-32
pubmed: 29706185
Cancer Invest. 2016 Sep 13;34(8):393-400
pubmed: 27558649
Sci Rep. 2021 Jan 18;11(1):1725
pubmed: 33462277
Asian Pac J Cancer Prev. 2013;14(5):2689-98
pubmed: 23803016
J Biomed Biotechnol. 2011;2011:567305
pubmed: 22007144
Cancer Manag Res. 2019 Jun 05;11:5163-5169
pubmed: 31239771
Cancer Biol Ther. 2022 Dec 31;23(1):34-50
pubmed: 34978469
Int J Mol Cell Med. 2021 Winter;10(1):45-55
pubmed: 34268253
Nat Rev Dis Primers. 2020 Nov 26;6(1):92
pubmed: 33243986
Biomed Pharmacother. 2020 May;125:109962
pubmed: 32106373
Int J Oncol. 2009 Apr;34(4):897-903
pubmed: 19287946
Curr Opin Otolaryngol Head Neck Surg. 2012 Apr;20(2):142-7
pubmed: 22249168
Acta Pharm Sin B. 2015 Sep;5(5):378-89
pubmed: 26579469
Eur J Cancer. 2005 Nov;41(16):2449-61
pubmed: 16199154
J Mater Chem B. 2021 Aug 4;9(30):6006-6016
pubmed: 34282440
Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14152-7
pubmed: 20660764
Sci Rep. 2017 Oct 31;7(1):14419
pubmed: 29089545
Cell Cycle. 2010 May;9(9):1722-8
pubmed: 20404562
Cancer Sci. 2022 Jan;113(1):319-333
pubmed: 34714590
J Oral Maxillofac Pathol. 2018 Sep-Dec;22(3):325-331
pubmed: 30651675
Oncol Lett. 2019 Jan;17(1):1257-1266
pubmed: 30655893
Cancers (Basel). 2020 Jul 31;12(8):
pubmed: 32751922
Cancers (Basel). 2021 Jun 17;13(12):
pubmed: 34204259
Biomed Res Int. 2015;2015:549412
pubmed: 26146622
Antioxidants (Basel). 2022 Feb 15;11(2):
pubmed: 35204269
Crit Rev Oncog. 1993;4(4):435-49
pubmed: 8353142
J Pathol. 2014 Oct;234(2):190-202
pubmed: 24852265

Auteurs

Guya Diletta Marconi (GD)

Department of Medical, Oral and Biotechnological Sciences, University "G. d'Annunzio" Chieti-Pescara, Via dei Vestini, 31, 66100 Chieti, Italy.

Ylenia Della Rocca (Y)

Department of Innovative Technologies in Medicine & Dentistry, University "G. d'Annunzio" Chieti-Pescara, Via dei Vestini, 31, 66100 Chieti, Italy.

Luigia Fonticoli (L)

Department of Innovative Technologies in Medicine & Dentistry, University "G. d'Annunzio" Chieti-Pescara, Via dei Vestini, 31, 66100 Chieti, Italy.

Francesco Melfi (F)

Department of Pharmacy, University "G. d'Annunzio" Chieti-Pescara, Via dei Vestini 31, 66100 Chieti, Italy.

Thangavelu Soundara Rajan (TS)

Department of Biotechnology, Karpagam Academy of Higher Education, Coimbatore 641021, India.
Karpagam Cancer Research Centre, Karpagam Academy of Higher Education, Coimbatore 641021, India.

Simone Carradori (S)

Department of Pharmacy, University "G. d'Annunzio" Chieti-Pescara, Via dei Vestini 31, 66100 Chieti, Italy.

Jacopo Pizzicannella (J)

Ss. Annunziata Hospital, ASL 02 Lanciano-Vasto-Chieti, 66100 Chieti, Italy.

Oriana Trubiani (O)

Department of Innovative Technologies in Medicine & Dentistry, University "G. d'Annunzio" Chieti-Pescara, Via dei Vestini, 31, 66100 Chieti, Italy.

Francesca Diomede (F)

Department of Innovative Technologies in Medicine & Dentistry, University "G. d'Annunzio" Chieti-Pescara, Via dei Vestini, 31, 66100 Chieti, Italy.

Classifications MeSH